BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 7687471)

  • 1. Granulocyte colony-stimulating factor (rh G-CSF) as an adjunct to interferon alpha therapy of neutropenic patients with hairy cell leukemia.
    Lorber C; Willfort A; Ohler L; Jäger U; Schwarzinger I; Lechner K; Geissler K
    Ann Hematol; 1993 Jul; 67(1):13-6. PubMed ID: 7687471
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b.
    Glaspy JA; Souza L; Scates S; Narachi M; Blatt L; Ambersley J; Golde DW
    J Immunother (1991); 1992 Apr; 11(3):198-208. PubMed ID: 1381218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Granulocyte colony-stimulating factor (G-CSF) as an adjunct to induction chemotherapy of adult acute lymphoblastic leukemia (ALL).
    Scherrer R; Geissler K; Kyrle PA; Gisslinger H; Jäger U; Bettelheim P; Laczika K; Locker G; Scholten C; Sillaber C
    Ann Hematol; 1993 Jun; 66(6):283-9. PubMed ID: 7686404
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor.
    Glaspy JA; Baldwin GC; Robertson PA; Souza L; Vincent M; Ambersley J; Golde DW
    Ann Intern Med; 1988 Nov; 109(10):789-95. PubMed ID: 2461131
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Interferon-α suppressed granulocyte colony stimulating factor production is reversed by CL097, a TLR7/8 agonist.
    Tajuddin T; Ryan EJ; Norris S; Hegarty JE; O'Farrelly C
    J Gastroenterol Hepatol; 2010 Dec; 25(12):1883-90. PubMed ID: 21092001
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The use of interferon-alpha and granulocyte colony-stimulating factor in hairy cell leukaemia with aplastic marrow.
    Osterholz J; Wohlleber M; Kahnt C; Schumacher K
    Eur J Haematol; 1995 Aug; 55(2):140-2. PubMed ID: 7543058
    [No Abstract]   [Full Text] [Related]  

  • 7. Granulocyte colony-stimulating factor dosing in pegylated interferon alpha-induced neutropenia and its impact on outcome of anti-HCV therapy.
    Koirala J; Gandotra SD; Rao S; Sangwan G; Mushtaq A; Htwe TH; Adamski A; Blessman D; Khardori NM
    J Viral Hepat; 2007 Nov; 14(11):782-7. PubMed ID: 17927614
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defective synthesis of granulocyte-colony stimulating factor in pegylated interferon-alpha treated chronic hepatitis C patients with declining leukocyte counts.
    Durante-Mangoni E; Iardino P; Utili R; Adinolfi LE; Ruggiero G
    Antivir Ther; 2006; 11(5):637-40. PubMed ID: 16964833
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the potency of glycosylated and nonglycosylated recombinant human granulocyte colony-stimulating factors in neutropenic and nonneutropenic CD rats.
    Nohynek GJ; Plard JP; Wells MY; Zerial A; Roquet F
    Cancer Chemother Pharmacol; 1997; 39(3):259-66. PubMed ID: 8996530
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of recombinant canine granulocyte colony-stimulating factor as an inducer of granulopoiesis. A pilot study.
    Obradovich JE; Ogilvie GK; Powers BE; Boone T
    J Vet Intern Med; 1991; 5(2):75-9. PubMed ID: 2061868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of recombinant human granulocyte colony-stimulating factor on hematopoiesis in normal cats.
    Fulton R; Gasper PW; Ogilvie GK; Boone TC; Dornsife RE
    Exp Hematol; 1991 Sep; 19(8):759-67. PubMed ID: 1714401
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Recombinant human granulocyte colony-stimulating factor promotes wound healing in a patient with congenital neutropenia.
    Besner GE; Glick PL; Karp MP; Wang WC; Lobe TE; White CR; Cooney DR
    J Pediatr Surg; 1992 Mar; 27(3):288-90; discussion 291. PubMed ID: 1380074
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Recombinant human granulocyte colony stimulating factor in cyclic neutropenia: use of a new 3-day-a-week regimen.
    Jayabose S; Tugal O; Sandoval C; Li K
    Am J Pediatr Hematol Oncol; 1994 Nov; 16(4):338-40. PubMed ID: 7526722
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effective stimulation of neutropoiesis with rh G-CSF in dyskeratosis congenita: a case report.
    Oehler L; Reiter E; Friedl J; Kabrna E; Haas OA; Rosenkranz A; Lechner K; Geissler K
    Ann Hematol; 1994 Dec; 69(6):325-7. PubMed ID: 7527662
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human recombinant granulocyte colony-stimulating factor for the treatment of autoimmune neutropenia.
    Takahashi K; Taniguchi S; Akashi K; Fujimoto K; Sibuya T; Ishibashi H; Harada M; Niho Y
    Acta Haematol; 1991; 86(2):95-8. PubMed ID: 1719726
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia is effective and reduces infectious complications.
    Lauria F; Bocchia M; Marotta G; Raspadori D; Zinzani PL; Rondelli D
    Haematologica; 1999 Jan; 84(1):22-5. PubMed ID: 10091389
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The effect of recombinant human granulocyte colony-stimulating factor (rG-CSF) on childhood neutropenias].
    Ueda K; Hanawa Y; Takaku F; Asano S; Tsukimoto I; Tsuchida M; Sato T; Ohira M; Hoshi Y; Nishihira K
    Rinsho Ketsueki; 1991 Mar; 32(3):212-20. PubMed ID: 1710294
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of granulocyte-colony stimulating factor on empiric therapy with flomoxef sodium and tobramycin in febrile neutropenic patients with hematological malignancies. Kan-etsu Hematological Disease and Infection Study Group.
    Yoshida M; Karasawa M; Naruse T; Fukuda M; Hirashima K; Oh H; Ninomiya H; Abe T; Saito K; Shishido H; Moriyama Y; Shibata A; Motoyoshi K; Nagata N; Miura Y
    Int J Hematol; 1999 Feb; 69(2):81-8. PubMed ID: 10071455
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a formulary change from granulocyte colony-stimulating factor to granulocyte-macrophage colony-stimulating factor on outcomes in patients treated with myelosuppressive chemotherapy.
    Wong SF; Chan HO
    Pharmacotherapy; 2005 Mar; 25(3):372-8. PubMed ID: 15843284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose escalation study of recombinant human granulocyte-colony-stimulating factor (KRN8601) in patients with advanced malignancy.
    Eguchi K; Sasaki S; Tamura T; Sasaki Y; Shinkai T; Yamada K; Soejima Y; Fukuda M; Fujihara Y; Kunitou H
    Cancer Res; 1989 Sep; 49(18):5221-4. PubMed ID: 2475245
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.